Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · U.S. Physical Therapy (USPH)

USPH Q2 revenue up 8.5% to $214.1 million, but EPS falls to $0.25

Mixed Impact 3 of 5 earnings Written later

U.S. Physical Therapy reported second-quarter 2026 net revenue of $214.1 million, up 8.5% from a year earlier, while net income attributable to shareholders fell to $9.9 million, or $0.25 per share, from $12.4 million, or $0.58 per share. Management reaffirmed full-year 2026 adjusted EBITDA guidance of $102.0 million to $106.0 million and declared a $0.46 quarterly dividend. For shareholders, revenue growth was offset by lower profit, and the physical therapy gross profit margin narrowed to 19.5% from 21.2%.

Key points

  • Q2 2026 net revenue of $214.1 million, up 8.5% from Q2 2025
  • Net income attributable to USPH shareholders of $9.9 million ($0.25 per share) versus $12.4 million ($0.58 per share) a year earlier
  • Full-year 2026 adjusted EBITDA guidance of $102.0 million to $106.0 million reaffirmed
  • Quarterly dividend of $0.46 payable September 11, 2026, to holders of record on August 21, 2026

The filing

CompanyU.S. Physical Therapy (USPH)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:10 PM ET
Accession number0000885978-26-000042

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.